Staphylococcus aureus binds factor H to moderate complement host defense

金黄色葡萄球菌结合 H 因子以调节补体宿主防御

基本信息

  • 批准号:
    7825398
  • 负责人:
  • 金额:
    $ 17.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-05-05 至 2011-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Staphylococcus aureus is a major health threat in the United States causing skin abscesses, bone infections, joint infections, pneumonias, heart infections, post-operative infections, and infections of implanted devices. Of international concern is the rapidly increasing number of infections caused by methicillin-resistant S. aureus (MRSA). The long-term objective of this proposal is to elucidate S. aureus mechanisms that facilitate evasion of humoral host defense functions as a prerequisite to the development of novel therapies to prevent or attenuate disease. The experimental focus of this proposal is to identify S. aureus cell wall components that bind the host complement regulatory protein factor H and to elucidate the immunomodulatory actions of factor H on the S. aureus surface. Factor H is a serum protein that controls complement activation by destabilizing critical convertases along the complement cascade. The proposed work will build upon our previously published findings that S. aureus binds factor H as well as our new preliminary findings that at least two cell wall components of S. aureus bind purified factor H on overlay Western blot assay. We shall take advantage of the investigator's humoral immune expertise and the proteomic expertise of the George L. Wright Jr. Center for Biomedical Proteomics at EVMS to achieve two specific aims: 1) elucidate the role of factor H binding to S. aureus on complement-mediated host defenses, 2) identify S. aureus cell wall protein(s) that bind factor H. In aim 1 we will use standard microbiologic and complement techniques to measure the effect of factor H in the destabilization of the alternative pathway C3-convertase and the terminal complement cascade C5-convertases on the S. aureus surface. In aim 2 we will use standard protein purification techniques coupled with tandem mass spectrometry to identify S. aurues cell wall components that bind factor H. PUBLIC HEALTH RELEVANCE: The proposed project will characterize interactions between Staphylococcus aureus cell wall and the host immuno-regulatory protein factor H. Understanding how this bacteria manipulates factor H will help identify new targets for prevention and treatment of Staphylococcus aureus infections.
描述(由申请方提供):金黄色葡萄球菌是美国的一种主要健康威胁,可引起皮肤脓肿、骨感染、关节感染、肺炎、心脏感染、术后感染和植入器械感染。引起国际关注的是由耐甲氧西林沙门氏菌引起的感染数量迅速增加。金黄色葡萄球菌(MRSA)。本建议的长期目标是阐明S。促进逃避体液宿主防御功能的金黄色葡萄球菌机制是开发预防或减轻疾病的新疗法的先决条件。本方案的实验重点是鉴定S.金黄色葡萄球菌细胞壁成分结合宿主补体调节蛋白因子H,并阐明因子H对金黄色葡萄球菌的免疫调节作用。金黄色表面。因子H是一种血清蛋白,其通过使补体级联反应中的关键转化酶沿着不稳定来控制补体活化。建议的工作将建立在我们以前发表的研究结果,S。金黄色葡萄球菌结合因子H以及我们的新的初步发现,至少有两个细胞壁成分的金黄色葡萄球菌。金黄色葡萄球菌结合纯化的H因子。我们将利用研究者的体液免疫专业知识和乔治L.小赖特中心的生物医学蛋白质组学在EVMS,以实现两个具体的目标:1)阐明H因子结合S的作用。金黄色葡萄球菌对补体介导的宿主防御的影响,2)鉴定S.结合因子H的金黄色葡萄球菌细胞壁蛋白。在目标1中,我们将使用标准的微生物学和补体技术来测量因子H在S.金黄色表面。在目标2中,我们将使用标准蛋白纯化技术结合串联质谱来鉴定S。增加细胞壁中结合H因子的成分。公共卫生关系:拟议的项目将表征金黄色葡萄球菌细胞壁和宿主免疫调节蛋白因子H之间的相互作用。了解这种细菌如何操纵H因子将有助于确定预防和治疗金黄色葡萄球菌感染的新靶点。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
New potential role of serum apolipoprotein E mediated by its binding to clumping factor A during Staphylococcus aureus invasive infections to humans.
  • DOI:
    10.1099/jmm.0.000010
  • 发表时间:
    2015-04
  • 期刊:
  • 影响因子:
    3
  • 作者:
    W. Elkhatib;P. Hair;J. Nyalwidhe;K. Cunnion
  • 通讯作者:
    W. Elkhatib;P. Hair;J. Nyalwidhe;K. Cunnion
Staphylococcus aureus surface protein SdrE binds complement regulator factor H as an immune evasion tactic.
  • DOI:
    10.1371/journal.pone.0038407
  • 发表时间:
    2012
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Sharp JA;Echague CG;Hair PS;Ward MD;Nyalwidhe JO;Geoghegan JA;Foster TJ;Cunnion KM
  • 通讯作者:
    Cunnion KM
Disruption of the alternative pathway convertase occurs at the staphylococcal surface via the acquisition of factor H by Staphylococcus aureus.
通过金黄色葡萄球菌获取 H 因子,在葡萄球菌表面发生旁路转化酶的破坏。
  • DOI:
    10.1016/j.molimm.2010.11.014
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    3.6
  • 作者:
    Sharp,JuliaA;Cunnion,KenjiM
  • 通讯作者:
    Cunnion,KenjiM
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KENJI Mason CUNNION其他文献

KENJI Mason CUNNION的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KENJI Mason CUNNION', 18)}}的其他基金

Peptide inhibition of complement-mediated hemolysis after xenotransfusion.
异种输血后补体介导的溶血的肽抑制。
  • 批准号:
    9129167
  • 财政年份:
    2016
  • 资助金额:
    $ 17.94万
  • 项目类别:
Staphylococcus aureus binds factor H to moderate complement host defense
金黄色葡萄球菌结合 H 因子以调节补体宿主防御
  • 批准号:
    7642971
  • 财政年份:
    2009
  • 资助金额:
    $ 17.94万
  • 项目类别:
Complement and the Clearance of Staphylococcus aureus
金黄色葡萄球菌的补体和清除
  • 批准号:
    6621594
  • 财政年份:
    2002
  • 资助金额:
    $ 17.94万
  • 项目类别:
Complement and the Clearance of Staphylococcus aureus
金黄色葡萄球菌的补体和清除
  • 批准号:
    7033007
  • 财政年份:
    2002
  • 资助金额:
    $ 17.94万
  • 项目类别:
Complement and the Clearance of Staphylococcus aureus
金黄色葡萄球菌的补体和清除
  • 批准号:
    6869638
  • 财政年份:
    2002
  • 资助金额:
    $ 17.94万
  • 项目类别:
Complement and the Clearance of Staphylococcus aureus
金黄色葡萄球菌的补体和清除
  • 批准号:
    6435230
  • 财政年份:
    2002
  • 资助金额:
    $ 17.94万
  • 项目类别:
Complement and the Clearance of Staphylococcus aureus
金黄色葡萄球菌的补体和清除
  • 批准号:
    6729197
  • 财政年份:
    2002
  • 资助金额:
    $ 17.94万
  • 项目类别:
Complement and the Clearance of Staphylococcus aureus
金黄色葡萄球菌的补体和清除
  • 批准号:
    6653926
  • 财政年份:
    2002
  • 资助金额:
    $ 17.94万
  • 项目类别:

相似海外基金

A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
  • 批准号:
    24K02286
  • 财政年份:
    2024
  • 资助金额:
    $ 17.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
  • 批准号:
    2420924
  • 财政年份:
    2024
  • 资助金额:
    $ 17.94万
  • 项目类别:
    Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
  • 批准号:
    10596047
  • 财政年份:
    2023
  • 资助金额:
    $ 17.94万
  • 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
  • 批准号:
    10742028
  • 财政年份:
    2023
  • 资助金额:
    $ 17.94万
  • 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
  • 批准号:
    BB/X017540/1
  • 财政年份:
    2023
  • 资助金额:
    $ 17.94万
  • 项目类别:
    Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
  • 批准号:
    LP210301365
  • 财政年份:
    2023
  • 资助金额:
    $ 17.94万
  • 项目类别:
    Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
  • 批准号:
    10730832
  • 财政年份:
    2023
  • 资助金额:
    $ 17.94万
  • 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
  • 批准号:
    10659841
  • 财政年份:
    2023
  • 资助金额:
    $ 17.94万
  • 项目类别:
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
  • 批准号:
    576545-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 17.94万
  • 项目类别:
    Idea to Innovation
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
  • 批准号:
    BB/V016067/1
  • 财政年份:
    2022
  • 资助金额:
    $ 17.94万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了